BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32266798)

  • 1. Characterizing the efficacy and trends of adjuvant therapy versus observation in women with early stage (uterine confined) leiomyosarcoma: a National Cancer Database study.
    Costales AB; Radeva M; Ricci S
    J Gynecol Oncol; 2020 May; 31(3):e21. PubMed ID: 32266798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study.
    Seagle BL; Sobecki-Rausch J; Strohl AE; Shilpi A; Grace A; Shahabi S
    Gynecol Oncol; 2017 Apr; 145(1):61-70. PubMed ID: 28317559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of adjuvant treatment and prognostic factors in stage I uterine leiomyosarcoma patients treated in Commission on Cancer®-accredited facilities.
    Vaz J; Tian C; Richardson MT; Chan JK; Mysona D; Rao UN; Powell MA; Shriver CD; Hamilton CA; Casablanca Y; Maxwell GL; Darcy KM
    Gynecol Oncol; 2020 Apr; 157(1):121-130. PubMed ID: 31954536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study.
    Guttmann DM; Li H; Sevak P; Grover S; Jacobson G; Feldman A; Rubin S; Chu C; Bhatia S; Elshaikh MA; Lin LL
    Int J Gynecol Cancer; 2016 Jan; 26(1):141-8. PubMed ID: 26509850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant gemcitabine-docetaxel chemotherapy for stage I uterine leiomyosarcoma: Trends and survival outcomes.
    Littell RD; Tucker LY; Raine-Bennett T; Palen TE; Zaritsky E; Neugebauer R; Embry-Schubert J; Lentz SE
    Gynecol Oncol; 2017 Oct; 147(1):11-17. PubMed ID: 28747255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?
    Ricci S; Giuntoli RL; Eisenhauer E; Lopez MA; Krill L; Tanner EJ; Gehrig PA; Havrilesky LJ; Secord AA; Levinson K; Frasure H; Celano P; Fader AN
    Gynecol Oncol; 2013 Dec; 131(3):629-33. PubMed ID: 24016408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilization and outcomes of adjuvant therapy for stage II and III uterine leiomyosarcoma.
    Diggs A; Sia TY; Huang Y; Gockley A; Melamed A; Khoury-Collado F; St Clair C; Hou JY; Hershman DL; Wright JD
    Gynecol Oncol; 2022 Aug; 166(2):308-316. PubMed ID: 35660331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in the treatment of uterine leiomyosarcoma in the Medicare population.
    Foley OW; Rauh-Hain JA; Clemmer J; Clark RM; Hall T; Diver EJ; Schorge JO; del Carmen MG
    Int J Gynecol Cancer; 2015 Mar; 25(3):453-8. PubMed ID: 25628107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival outcomes of adjuvant radiotherapy and chemotherapy in women with stage I serous papillary and clear cell carcinoma of the endometrium: a Korean multicenter study.
    Kim M; Kwon BS; Chang HK; Lee S; Chang SJ; Choi JY; Park SY; Lee M; Ryu HS; Kim YB
    J Gynecol Oncol; 2019 May; 30(3):e44. PubMed ID: 30887761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores.
    Chen J; Wu X; Christos PJ; Formenti S; Nagar H
    Breast Cancer Res; 2018 Apr; 20(1):26. PubMed ID: 29661221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of adjuvant chemotherapy in early stage uterine leiomyosarcoma: A systematic review and meta-analysis.
    Bogani G; FucĂ  G; Maltese G; Ditto A; Martinelli F; Signorelli M; Chiappa V; Scaffa C; Sabatucci I; Lecce F; Raspagliesi F; Lorusso D
    Gynecol Oncol; 2016 Nov; 143(2):443-447. PubMed ID: 27481579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant therapy in stage III endometrial cancer: treatment outcomes and survival. a single-institution retrospective study.
    Kuku S; Williams M; McCormack M
    Int J Gynecol Cancer; 2013 Jul; 23(6):1056-64. PubMed ID: 23765205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients.
    Mancari R; Signorelli M; Gadducci A; Carinelli S; De Ponti E; Sesana S; Corso S; Chiappa V; Colombo N; Lissoni AA
    Gynecol Oncol; 2014 Jun; 133(3):531-6. PubMed ID: 24631454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant Therapy Use and Survival in Stage II Endometrial Cancer.
    Lester-Coll NH; Young MR; Park HS; Ratner ES; Litkouhi B; Damast S
    Int J Gynecol Cancer; 2017 Nov; 27(9):1904-1911. PubMed ID: 28763364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant Chemotherapy in Uterine Leiomyosarcoma: Trends and Factors Impacting Usage.
    Patel D; Handorf E; von Mehren M; Martin L; Movva S
    Sarcoma; 2019; 2019():3561501. PubMed ID: 30881199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Options for Adjuvant Therapy for Uterine Leiomyosarcoma.
    Friedman CF; Hensley ML
    Curr Treat Options Oncol; 2018 Feb; 19(2):7. PubMed ID: 29417238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of perioperative characteristics on the recurrence risk and survival of patients with uterine leiomyosarcoma.
    Gracia M; Yildirim Y; Macuks R; Mancari R; Achimas-Cadariu P; Cusine-Lopez L; Novak Z; Dallaku K; Zapardiel I;
    Int J Gynaecol Obstet; 2023 Dec; 163(3):868-874. PubMed ID: 37485666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lymphovascular space invasion.
    Simpkins F; Papadia A; Kunos C; Michener C; Frasure H; AbuShahin F; Mariani A; Bakkum-Gamez JN; Landrum L; Moore K; Thomas SG; Windhorn A; Rose PG
    Int J Gynecol Cancer; 2013 Jan; 23(1):98-104. PubMed ID: 23221731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of stage II endometrial cancer and subsequent oncologic outcomes: a National Cancer Database study.
    Vetter MH; Bixel K; Felix AS
    J Gynecol Oncol; 2020 Nov; 31(6):e84. PubMed ID: 33078593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma.
    Matsuo K; Omatsu K; Ross MS; Johnson MS; Yunokawa M; Klobocista MM; Im DD; Bush SH; Ueda Y; Takano T; Blake EA; Hasegawa K; Baba T; Shida M; Satoh S; Yokoyama T; Machida H; Adachi S; Ikeda Y; Iwasaki K; Miyake TM; Yanai S; Nishimura M; Nagano T; Takekuma M; Takeuchi S; Pejovic T; Shahzad MM; Ueland FR; Kelley JL; Roman LD
    Gynecol Oncol; 2017 Apr; 145(1):78-87. PubMed ID: 28215838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.